The global transthyretin amyloid cardiomyopathy treatment market is primarily driven by the increasing prevalence of ATTR-CM disease globally. Transthyretin amyloid cardiomyopathy, also known as ATTR-CM, is a rare, progressive, and frequently life-threatening heart disease caused by abnormal deposits of amyloid protein consisting of misfolded transthyretin (TTR) in the heart. ATTR-CM treatment aims to eliminate the pathogenic protein deposits in the heart along with symptomatic management for cardiomyopathy. The currently approved treatment options include tafamidis, inotersen, and diflunisal which are designed to reduce amyloid deposition in tissues and address cardiomyopathy.
The global transthyretin amyloid cardiomyopathy treatment market is estimated to be valued at US$ 1943.69 Bn in 2024 and is expected to exhibit a CAGR of 8.0% over the forecast period from 2024 to 2031.
Key Takeaways
Key players operating in the transthyretin amyloid cardiomyopathy treatment market are DermaSweep Inc., Lifetrons Switzerland AG, Trophy Skin,PMD Beauty, Dermaglow, ImageDerm Inc., Clairderm Medical Aesthetics, Sylvan Company, Altair Instruments, Koninklijke Philips, Microderm GLO Skincare USA, Silhouet-Tone, and Edge Systems LLC. (HydraFacial), among others. The key players in the market are focusing on new product approvals and launches to expand their product portfolios and strengthen market presence. Increasing research funding from foundations along with advancements in understanding disease pathogenesis has accelerated treatment research in recent years. ATTR-CM has gained more attention and awareness among treating physicians as well as the general population.
The growing prevalence of ATTR-CM cases and lack of an established cure is fueling the demand for disease modifying therapies. According to estimates, the prevalence of ATTR amyloidosis is approximately 50,000-100,000 persons globally, with around 3,000-5,000 new cases reported each year. Countries with large geriatric population bases in Europe and Asia Pacific are witnessing a rising disease burden. Significant unmet needs persist regarding disease diagnosis, long-term effectiveness and safety of existing drugs, and management of cardiomyopathy symptoms. These factors collectively create a lucrative growth environment for ATTR-CM treatment providers.
Global expansion strategies by key companies include collaborative agreements, acquisitions, and investments for tech upgrades and capacity expansions. Many biopharma players are investing in multi-regional clinical studies to accelerate approval timelines and bolster commercialization in new markets. The market is also witnessing initiatives towards developing new classes of drugs with promising mechanisms of action and more convenient routes of administration.
Market drivers:
The key driver fueling the Transthyretin Amyloid Cardiomyopathy Treatment Market Growth is the rising geriatric population globally that is susceptible to ATTR-CM. Age is a major disease risk factor as the prevalence increases considerably after the age of 60 years. According to United Nations data, the population aged 60 years and above is expected to reach nearly 2.1 billion worldwide by 2050 from 1 billion in 2019. Growing life expectancy along with advanced healthcare has raised the risk of protein misfolding diseases like ATTR-CM emerging as significant public health concerns. Development of new diagnostic methods and biomarkers is also driving earlier disease detection and treatment-seeking rate.
Impact of the current geopolitical situation on the Transthyretin Amyloid Cardiomyopathy Treatment Market growth
The ongoing geopolitical tensions and conflicts around the world are posing challenges for the growth of the Transthyretin Amyloid Cardiomyopathy Treatment market. The Russia-Ukraine war has disrupted global supply chains and increased economic uncertainties. This has hampered research activities and clinical trials for new treatment options. Rising inflation rates are also reducing the affordability of advanced therapies among patients in many countries. Furthermore, international trade restrictions and sanctions are disrupting the exports and imports of key ingredients and medical devices. The ongoing tensions between China and the US regarding Taiwan could further strain global trade networks and investments in the life sciences sector. However, governments and researchers are taking initiatives to diversify supply sources and concentrate production locally. New collaborative models are also being explored to accelerate research while overcoming geopolitical challenges.
Impact of geographical regions on the Transthyretin Amyloid Cardiomyopathy Treatment Market
North America currently accounts for the largest share of the global Transthyretin Amyloid Cardiomyopathy Treatment market in terms of value. This can be attributed to the rising geriatric population, growing diagnosis rates, strong reimbursement structure, and presence of major market players in the region. The US holds a significant share within the North American market. However, Europe is emerging as the fastest growing regional market due to increasing awareness, supportive regulations, and large patient pool. The rising healthcare expenditures and improving access to treatments are also fueling the European market growth. Meanwhile, the Asia Pacific market is expected to offer most lucrative opportunities over the forecast period driven by growing medical tourism, rising investments in healthcare infrastructure and expanding base of privately insured population across major Asian countries.
Geographical region witnessing fastest growth in the Transthyretin Amyloid Cardiomyopathy Treatment Market
The Asia Pacific region is poised to witness the fastest growth in the global Transthyretin Amyloid Cardiomyopathy Treatment market during the forecast period. This can be attributed to rapidly growing economies, rising healthcare investments, increasing medical insurance coverage, and expansion of healthcare infrastructure in the region. Moreover, growing trade partnerships and collaborations between countries are helping to boost research activities and facilitate technology transfers in the life sciences domain. Countries like China, India, Japan, and South Korea are emerging as global outsourcing hubs and are attracting significant investments for pharmaceutical and biotech facilities. Furthermore, rising awareness about rare diseases, growing geriatric population, and improving access to advanced healthcare are fueling the regional market demand. The governments are also taking initiatives to strengthen regulations to promote innovations. All these factors are expected to drive the Asia Pacific region to the forefront of global Transthyretin Amyloid Cardiomyopathy Treatment market in the upcoming years.
Get more insights on Transthyretin Amyloid Cardiomyopathy Treatment Market
Chemotherapy treatments, cardiac medications, targeted therapies, organ transplant, dialysis, and autologous blood stem cell transplant are all utilized to treat amyloidosis.
Amyloid light chain amyloidosis, autoimmune amyloidosis, familial amyloidosis, wide-type (or senile) amyloidosis, dialysis-related, and cardiac amyloidosis are the most prevalent forms of amyloidosis.
The aggregation and deposition of mutant and wild-type transthyretin (TTR) protein in the heart characterizes familial amyloid cardiomyopathy (FAC) or transthyretin amyloid cardiomyopathy (ATTR-CM).
FAC may have an impact on how electrical signals go through the heart (conduction system).
Alnylam Pharmaceuticals, Inc., an RNAi therapeutics company, announced positive results from a Phase 3b open-label study to evaluate the safety, efficacy, and pharmacokinetics of patisiran in patients with hereditary ATTR (hATTR) amyloidosis who progressed to polyneuropathy after receiving an orthotopic liver transplant in June 2021.
Inotersen is a 2-MOE antisense oligonucleotide drug that reduces the quantity of mutant and normal TTR produced by the liver.
